The fluoroquinolones: The last samurai?

Clinical Infectious Diseases

Volumn 41, Issue 2 SUPPL., 2005, Pages

  Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; GEMIFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; PRIORITY JOURNAL;

EID: 21844460232     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428050     Document Type: Editorial

References (8)

1. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis 2005;41(Suppl 2): S113-9 (in this issue).
2. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2): S120-6 (in this issue).
3. Wispelwey B. Clinical implications of pharmacokinetics and pharmcodynamics of fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2): S127-35 (in this issue).
4. Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41(Suppl 2):S136-43 (in this issue).
5. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41(Suppl 2):S144-57 (in this issue).
6. Niederman MS. Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin Infect Dis 2005;41(Suppl 2):S158-66 (in this issue).
7. Anon JB. Current management of acute bacterial rhinosinusitis and the role of moxifloxacin. Clin Infect Dis 2005;41(Suppl 2):S167-76 (in this issue).
8. Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41(Suppl 2): S177-85 (in this issue).